Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact

被引:37
|
作者
Dowling, M. R. [1 ,2 ,3 ,4 ]
Li, S. [5 ]
Dey, B. R. [6 ]
McAfee, S. L. [6 ]
Hock, H. R. [6 ]
Spitzer, T. R. [6 ]
Chen, Y-B [6 ]
Ballen, K. K. [7 ]
机构
[1] Walter & Eliza Hall Inst Med Res, Immunol Div, Parkville, Vic, Australia
[2] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[4] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[7] Univ Virginia, Canc Ctr, Univ Virginia Hlth Syst, Dept Med,Stem Cell Transplant Program, 1215 Lee St, Charlottesville, VA 22903 USA
基金
英国医学研究理事会;
关键词
BONE-MARROW-TRANSPLANTATION; REVERSIBLE ENCEPHALOPATHY SYNDROME; CORD BLOOD TRANSPLANTATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NERVOUS-SYSTEM COMPLICATIONS; HIGH-DOSE CHEMOTHERAPY; LIMBIC ENCEPHALITIS; COMPETING RISK; CYCLOSPORINE-A; TACROLIMUS;
D O I
10.1038/bmt.2017.239
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of NCs in the first 5 years after HCT. We determined the incidence of central nervous system (CNS) infection, intracranial hemorrhage, ischemic stroke, metabolic encephalopathy, posterior reversal encephalopathy syndrome, seizure and peripheral neuropathy. In all, 50 patients experienced 63 NCs-37 early (<= day + 100), 21 late (day + 101 to 2 years) and 5 very late (2 to 5 years). The 1- and 5-year cumulative incidences of all NCs were 15.6% and 19.2%, respectively, and of CNS complication (CNSC; all of the above complications except peripheral neuropathy) were 12.2 and 14.5%. Risk factors for CNSC were age (hazard ratio (HR) = 1.06 per year, P = 0.0034), development of acute GvHD grade III-IV (HR = 2.78, P=0.041), transfusion-dependent thrombocytopenia (HR = 3.07, P = 0.025) and delayed platelet engraftment (> 90th centile; HR = 2.77, P = 0.043). CNSCs negatively impacted progression-free survival (HR = 2.29, P = 0.0001), overall survival (HR = 2.63, P < 0.0001) and non-relapse mortality (HR = 8.51, P < 0.0001). NCs after HCT are associated with poor outcomes, and usually occur early after HCT.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 50 条
  • [21] Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation
    Kubo, Hiroyuki
    Imataki, Osamu
    Fukumoto, Tetsuya
    Kawanaka, Yui
    Ishida, Tomoya
    Kubo, Yukiko Hamasaki
    Kida, Jun-ichiro
    Uemura, Makiko
    Fujita, Haruyuki
    Kadowaki, Norimitsu
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [22] Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation
    Hiroyuki Kubo
    Osamu Imataki
    Tetsuya Fukumoto
    Yui Kawanaka
    Tomoya Ishida
    Yukiko Hamasaki Kubo
    Jun-ichiro Kida
    Makiko Uemura
    Haruyuki Fujita
    Norimitsu Kadowaki
    Scientific Reports, 13 (1)
  • [23] Risk Factors of Cytomegalovirus Retinitis Occurrence After Allogeneic Hematopoietic Stem Cell Transplantation
    Zhang, Hai-Qing
    Feng, Jing-Hong
    Li, Sheng-Jun
    Yang, Yun-Xian
    Long, Yan
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2025, 33 (02) : 295 - 302
  • [24] Graft failure after allogeneic hematopoietic stem cell transplantation: Definition and risk factors
    Alcazer, Vincent
    de Latour, Regis Peffault
    Ader, Florence
    Labussiere-Wallet, Helene
    BULLETIN DU CANCER, 2019, 106 (06) : 574 - 583
  • [25] Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation
    Na, K-S
    Yoo, Y-S
    Mok, J. W.
    Lee, J. W.
    Joo, C-K
    BONE MARROW TRANSPLANTATION, 2015, 50 (11) : 1459 - 1464
  • [26] Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation
    K-S Na
    Y-S Yoo
    J W Mok
    J W Lee
    C-K Joo
    Bone Marrow Transplantation, 2015, 50 : 1459 - 1464
  • [27] Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation
    Shen, Biao
    Ma, Yueshen
    Zhang, Haixiao
    Wang, Mingyang
    Liu, Jia
    Cao, Jiaxin
    Guo, Wenwen
    Feng, Dan
    Yang, Donglin
    Zhang, Rongli
    Chen, Xin
    Ma, Qiaoling
    Zhai, Weihua
    Feng, Sizhou
    Han, Mingzhe
    Pang, Aiming
    Jiang, Erlie
    BLOOD SCIENCE, 2022, 4 (02): : 83 - 88
  • [28] The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes
    Uhm, Jieun
    Hamad, Nada
    Gupta, Vikas
    Kuruvilla, John
    Messner, Hans A.
    Seftel, Matthew
    Lipton, Jeffrey H.
    Kim, Dennis D.
    BLOOD, 2014, 124 (21)
  • [29] Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors
    Tan, Wanxia
    He, Yuelin
    Feng, Xiaoqin
    Wu, Xuedong
    Li, Chunfu
    Liao, Jianyun
    Liu, Huaying
    Liu, Xuan
    Pei, Fuyu
    Liu, Qiujun
    Liu, Xiaoting
    Ren, Yuqiong
    BLOOD, 2020, 136
  • [30] INVESTIGATION OF THE FREQUENCY AND RISK FACTORS OF CARDIAC COMPLICATIONS AFTER INITIAL ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
    Yanagisawa, Ryu
    Nakazawa, Hideyuki
    Harada, Mikiko
    Sakai, Hitoshi
    Nishina, Sayaka
    Kawakami, Toru
    Kawakami, Fumihiro
    Fujiwara, Shin-ichiro
    Motoki, Hirohiko
    Ito, Toshiro
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 535 - 535